Edesa Biotech (EDSA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$5.4M

Net income growth (year over year)

−209.10%

Net margin

—

Return on equity

−122.93%

EPS (trailing twelve months)

−$1.72

Book value per share

$0.04

P/E (trailing twelve months)

—

Price to book

4.06

Debt to assets

30.74%

Payout ratio

—

Dividend yield

—

Company profile

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

• How do I buy stock in Edesa Biotech (EDSA)?

  EDSA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.